Group 1: Dongshan Precision - Dongshan Precision reported a revenue of 27.071 billion yuan for the first three quarters, a year-on-year increase of 2.28% [1] - The net profit attributable to shareholders for the same period was 1.223 billion yuan, up 14.61% year-on-year [1] - In Q3, the company achieved a revenue of 10.115 billion yuan, a 2.82% increase year-on-year, but the net profit decreased by 8.19% to 465 million yuan [1] Group 2: Zhejiang Huayuan - Zhejiang Huayuan's revenue for the first three quarters reached 541 million yuan, reflecting an 18.64% year-on-year growth [1] - The net profit attributable to shareholders was 78.9528 million yuan, up 29.30% year-on-year [1] - In Q3, the revenue was 197 million yuan, a 16.72% increase, while the net profit grew by 6.05% to 20.5973 million yuan [1] Group 3: Yingboer - Yingboer reported a revenue of 2.358 billion yuan for the first three quarters, a significant increase of 46.70% year-on-year [2] - The net profit attributable to shareholders surged by 191.18% to 149 million yuan [2] - In Q3, the revenue was 989 million yuan, up 69.40%, and the net profit skyrocketed by 580.62% to 112 million yuan [2] Group 4: Yichang Technology - Yichang Technology's revenue for the first three quarters was 2.106 billion yuan, a 14.30% increase year-on-year [3] - The net profit attributable to shareholders fell by 46.84% to 38.0785 million yuan [3] - In Q3, the revenue was 715 million yuan, up 11.13%, while the net profit increased by 193.37% to 3.6538 million yuan [3] Group 5: Stanley - Stanley reported a revenue of 9.290 billion yuan for the first three quarters, a year-on-year increase of 17.91% [4] - The net profit attributable to shareholders was 815 million yuan, reflecting a 22.71% growth [4] - In Q3, the revenue reached 2.899 billion yuan, up 31.41%, and the net profit increased by 35.36% to 208 million yuan [4] Group 6: Wen's Shares - Wen's Shares reported a revenue of 75.788 billion yuan for the first three quarters, a slight decline of 0.03% year-on-year [6] - The net profit attributable to shareholders decreased by 18.29% to 5.256 billion yuan [6] - In Q3, the revenue was 25.937 billion yuan, down 9.76%, and the net profit fell sharply by 65.02% to 1.781 billion yuan [6] Group 7: China XD Electric - China XD Electric achieved a revenue of 16.959 billion yuan for the first three quarters, a year-on-year increase of 11.85% [7] - The net profit attributable to shareholders was 939 million yuan, up 19.29% [7] - In Q3, the revenue was 5.658 billion yuan, reflecting a 15.98% increase, while the net profit grew by 1.78% to 340 million yuan [7] Group 8: Huayi Group - Huayi Group reported a revenue of 35.708 billion yuan for the first three quarters, a decline of 5.02% year-on-year [8] - The net profit attributable to shareholders fell by 42.68% to 395 million yuan [8] - In Q3, the revenue was 11.708 billion yuan, down 9.75%, and the company reported a net loss of 92.7736 million yuan [8] Group 9: Zhiwei Intelligent - Zhiwei Intelligent's revenue for the first three quarters was 2.973 billion yuan, a 6.89% increase year-on-year [9] - The net profit attributable to shareholders rose by 59.3% to 131 million yuan [9] - In Q3, the revenue was 1.026 billion yuan, up 6.08%, and the net profit increased by 13.67% to 29.2356 million yuan [9] Group 10: Shiyi Da - Shiyi Da reported a revenue of 485 million yuan for the first three quarters, reflecting a 7.26% year-on-year growth [10] - The net profit attributable to shareholders was 30.3088 million yuan, up 12.37% [10] - In Q3, the revenue reached 176 million yuan, a 29.81% increase, while the net profit surged by 471.34% to 14.8444 million yuan [10] Group 11: Poly Developments - Poly Developments reported a revenue of 173.722 billion yuan for the first three quarters, a decline of 4.95% year-on-year [13] - The net profit attributable to shareholders fell by 75.31% to 1.929 billion yuan [13] - In Q3, the revenue was 56.865 billion yuan, up 30.65%, but the company reported a net loss of 782 million yuan [13] Group 12: Huadong Medicine - Huadong Medicine's subsidiary received FDA approval for clinical trials of DR10624 injection targeting severe hypertriglyceridemia [14] - DR10624 is a globally first-of-its-kind long-acting tri-specific agonist [14] Group 13: Lihua Microelectronics - Lihua Microelectronics announced a plan to reduce its shareholding by up to 3% due to operational needs [16] - The reduction will occur through centralized bidding and block trading from November 13, 2025, to February 12, 2026 [16] Group 14: Greebo - Greebo secured a significant order worth 60 million USD from a leading US home improvement retailer for lithium outdoor power equipment [17] - The order is expected to be delivered by the end of January 2026 [17] Group 15: ST Jingfeng - ST Jingfeng's stock will be subject to delisting risk warning due to the court's acceptance of creditor restructuring application [20] - The stock will resume trading on October 23, 2025, under the name "*ST Jingfeng" [20] Group 16: Yinxin Development - Yinxin Development plans to acquire 81.81% of Guangdong Changxing Semiconductor Technology Co., Ltd. [22] - The acquisition is expected to result in Yinxin Development gaining control over Changxing Semiconductor [22]

Core Viewpoint - The announcement from East China Pharmaceutical indicates that its subsidiary, Zhejiang Daer Biotechnology Co., Ltd., has received FDA approval for the clinical trial application of the DR10624 injection, targeting severe hypertriglyceridemia [1] Group 1: Clinical Trial Approval - The DR10624 injection has been approved by the FDA to conduct clinical trials in the United States for the indication of severe hypertriglyceridemia [1] - The drug has successfully completed Phase II clinical studies for severe hypertriglyceridemia, yielding positive topline results post-blinding [1] Group 2: Clinical Research Results - At the EASL Congress 2025, Daer Biotechnology reported that the Phase Ib/IIa clinical study of DR10624 for obesity combined with hypertriglyceridemia showed a maximum liver fat reduction of 89% and a relative triglyceride reduction exceeding 70% from baseline [1] - A Phase II clinical study for DR10624, targeting metabolic-associated fatty liver disease with high risk of liver fibrosis and alcohol-related fatty liver disease, is set to complete its first subject enrollment by April 2025 [1] Group 3: Additional Approvals - The clinical trial application for DR10624 targeting weight management in type 2 diabetes and overweight or obese populations has also been approved in China [1] - Daer Biotechnology submitted the clinical trial application for DR10624 to the FDA in September 2025 and has recently received approval [1]

格隆汇10月21日丨华东医药(000963.SZ)公布，控股子公司浙江道尔生物科技有限公司（简称"道尔生 物"）收到美国食品药品监督管理局（简称"美国FDA"）通知，由道尔生物申报的DR10624注射液药品 临床试验申请已获得美国FDA批准，可在美国开展临床试验，适应症为重度高甘油三酯血症 （SevereHypertriglyceridemia，SHTG）。DR10624是道尔生物自主研发的全球首创（First-in-class）的 靶向成纤维细胞生长因子21受体（Fibroblastgrowthfactor21receptor，FGF21R）、胰高血糖素受体 （Glucagonreceptor，GCGR）和胰高血糖素样肽-1受体（Glucagon-likepeptide-1receptor，GLP-1R）的长 效三特异性激动剂。DR10624由N端靶向GLP-1R/GCGR的嵌合肽段与工程化改造的IgG1Fc融合，并在 Fc的C末端融合重组的FGF21突变体。 ...

Core Viewpoint - The announcement indicates that East China Pharmaceutical's subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has received FDA approval for clinical trials of the drug DR10624 in the United States [2] Group 1 - East China Pharmaceutical's subsidiary, Daor Biotechnology, has successfully submitted a clinical trial application for the drug DR10624 [2] - The FDA's approval allows Daor Biotechnology to conduct clinical trials in the U.S. market [2]

北京商报讯（记者 王寅浩 宋雨盈）10月21日，华东医药发布公告称，公司控股子公司浙江道尔生物科 技有限公司收到美国食品药品监督管理局（FDA）通知，由道尔生物申报的DR10624注射液药品临床试 验申请已获得美国FDA批准，可在美国开展临床试验，适应症为重度高甘油三酯血症。 ...

Group 1 - Company Zhejiang Daor Bio-Tech Co., Ltd., a subsidiary of Huadong Medicine, has received approval from the U.S. FDA for its clinical trial application for the drug DR10624 injection [1] - The approved clinical trial is aimed at treating Severe Hypertriglyceridemia (SHTG) [1]

Core Viewpoint - The company announced that its subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has received approval from the U.S. FDA to conduct clinical trials for the drug DR10624, which targets severe hypertriglyceridemia (SHTG) [1] Group 1 - The clinical trial application for DR10624 injection has been approved by the U.S. FDA [1] - The approved indication for DR10624 is severe hypertriglyceridemia (SHTG) [1] - The approval allows the company to initiate clinical trials in the United States [1]

Core Viewpoint - The company announced that its subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has received FDA approval for the clinical trial application of the drug DR10624, which targets severe hypertriglyceridemia (SHTG) [1] Company Summary - Zhejiang Daor Biotechnology Co., Ltd. is a subsidiary of the company [1] - The approved drug, DR10624, is intended for the treatment of severe hypertriglyceridemia (SHTG) [1] - The FDA approval allows the company to conduct clinical trials in the United States [1] Industry Summary - The approval of DR10624 indicates potential growth opportunities in the biotechnology sector, particularly in treatments for severe hypertriglyceridemia [1]

Core Insights - The company announced that its subsidiary, Daor Bio, received FDA notification for the clinical trial application of DR10624 injection, which is approved for clinical trials in the U.S. for severe hypertriglyceridemia indications [1] - DR10624 is a globally innovative long-acting tri-specific agonist developed independently by Daor Bio, having previously completed Phase II clinical studies with positive topline results [1] - The uncertainty surrounding the drug's development is noted, but it is stated that this will not have a significant impact on the company's recent performance [1]

Core Viewpoint - The announcement by East China Pharmaceutical Co., Ltd. regarding its subsidiary Zhejiang Daor Biotechnology Co., Ltd.'s innovative long-acting triple agonist DR10624 for treating severe hypertriglyceridemia has been recognized as a groundbreaking clinical trial, set to be presented at the AHA 2025 conference [1][2]. Group 1 - The DR10624-201 study results have been selected for presentation at the AHA 2025, highlighting the scientific value and clinical prospects of DR10624 [1]. - The AHA 2025 conference will take place from November 7 to 10, 2025, in New Orleans, Louisiana, and is a premier event for showcasing the latest research in cardiovascular diseases [1]. - The study's lead researcher, Professor Li Jianping, will present the clinical data for the first time at the AHA annual meeting, marking a historic breakthrough for Chinese scholars in the field of cardiovascular research [2]. Group 2 - DR10624 is a first-in-class long-acting triple-target agonist, uniquely targeting FGFR1c/Klothoβ, GLP-1R, and GCGR, and is currently the fastest-developing FGF21 triple-target drug [2]. - The drug is also undergoing a Phase II clinical study in China for treating metabolic-associated fatty liver disease with high risk of liver fibrosis, with the first subject expected to be enrolled by April 2025 [2].